Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Hormonal Therapy

Therapeutic area intelligence for Hormonal Therapy with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
4
Catalysts
0
Companies
1

Companies

Stemline Therapeutics →

Assets

FDA →
ORSERDU →
Verity →

Recent signals(4)

RegulatoryJuly 3, 2026

FDA Approves Supplemental Applications for TRELSTAR

The FDA has approved supplemental applications for TRELSTAR, a triptorelin pamoate product.

RegulatoryJuly 1, 2026

FDA Accepts Supplemental NDA for TRELSTAR by Verity

The FDA has accepted a supplemental NDA for TRELSTAR, an injectable formulation of triptorelin pamoate.

RegulatoryJune 30, 2026

FDA Accepts Supplemental Application for ORSERDU (Elacestrant Hydrochloride)

The FDA has accepted a supplemental application for ORSERDU (elacestrant hydrochloride) from Stemline Therapeutics.

RegulatoryJune 22, 2026

FDA Grants Abiraterone Acetate ANDA208371 Approval Status

The FDA has granted application ANDA208371 for Abiraterone Acetate a status of Approved Pending (AP) under a supplemental submission.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.